Search

Displaying results 6731 - 6740 of 8974 in total
  1. Drug

    BHT-3034

    go.drugbank.com/drugs/DB18045
    Experimental

    BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]

  2. Drug

    XEN-D0501

    go.drugbank.com/drugs/DB18673
    Investigational

    XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.

  3. Drug

    Daphnetin

    go.drugbank.com/drugs/DB18965
    Investigational

    Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).

  4. Drug

    Radavirsen

    go.drugbank.com/drugs/DB15332
    Investigational

    Radavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).

  5. Drug

    Norleucine

    go.drugbank.com/drugs/DB15458
    Investigational

    Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women).

  6. Drug

    Aminaphthone

    go.drugbank.com/drugs/DB13039
    Investigational

    Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction.

  7. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are thought to reduce inflammation and associated damage.

  8. Drug

    7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

    go.drugbank.com/drugs/DB08550
    Experimental

    Potent reversible inhibitor of phenylethanolamine N-methyltransferase.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  10. Drug

    CTR-107

    go.drugbank.com/drugs/DB18583
    Experimental

    It is being investigated for the treatment of familial exudative vitreoretinopathy.